Education
About Us
Working with TipRanks
Follow Us
Esperion (ESPR)
NASDAQ:ESPR
ESPR Stock Chart & Stats
$3.35
-$0.02(-0.92%)
At close: 4:00 PM EST
$3.35
-$0.02(-0.92%)
Day’s Range― - ―
52-Week Range$0.69 - $4.18
Previous CloseN/A
Volume1.55M
Average Volume (3M)3.62M
Market Cap
$800.86M
Enterprise Value$1.17B
Total Cash (Recent Filing)$92.45M
Total Debt (Recent Filing)$600.99M
Price to Earnings (P/E)―
Beta2.44
Next Earnings
Mar 10, 2026EPS Estimate
0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding239,063,430
10 Day Avg. Volume2,525,028
30 Day Avg. Volume3,622,475
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-1.06
Price to Sales (P/S)1.24
P/FCF Ratio-17.18
Enterprise Value/Market Cap1.46
Enterprise Value/Revenue3.85
Enterprise Value/Gross Profit7.19
Enterprise Value/Ebitda-42.81
Forecast
1Y Price Target
$7.96Price Target Upside137.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.15
Revenue Forecast (FY)$397.96M
Bulls Say, Bears Say
Bulls Say
Commercial Uptake And Payer CoverageStrong commercial uptake among statin-intolerant patients paired with broad payer coverage supports sustained prescription growth and improved patient access.
Guideline EndorsementInclusion of bempedoic acid as the only new non-statin option in European cardiology guidelines provides strong clinical validation that should encourage specialist adoption.
Pipeline ExpansionNomination of ESP-2001 as a preclinical candidate and plans for a first-in-human trial broaden the pipeline into liver disease indications with significant unmet need.
Bears Say
Patent Litigation UncertaintyOngoing patent litigations create uncertainty around the timing of generic entry and may pressure pricing and expected market exclusivity.
Regulatory Hurdle For NEXLIZETHealth Canada request for additional manufacturing information on NEXLIZET introduces a regulatory hurdle that could delay approvals or limit market access.
Revenue Dependence On Partner PerformanceRevenue from the Japanese market depends on milestone payments and royalties tied to a partner's commercial performance, limiting direct control over sales outcomes.
Esperion News
ESPR FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest stock price was $0.69 and its highest was $4.17 in the past 12 months.
What is Esperion’s market cap?
Esperion’s market cap is $800.86M.
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is Mar 10, 2026 which is in 8 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on Nov 06, 2025. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.078 by -$0.082.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is 0.28.
How many shares outstanding does Esperion have?
Esperion has 239,063,430 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.078. Following the earnings report the stock price went down -14.966%.
Which hedge fund is a major shareholder of Esperion?
Currently, no hedge funds are holding shares in ESPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Esperion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.96 (137.61% Upside)
$7.96 (137.61% Upside)
Blogger Sentiment
Neutral
ESPR Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 968.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $232.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
101.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.89%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
ESPR Company Deck
ESPR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue growth, successful strategic initiatives, and international expansion. However, increased operating expenses and onetime financial impacts were noted as challenges. Overall, the highlights of growth and strategic progress outweigh the lowlights.View all ESPR earnings summariesESPR Stock 12 Month Forecast
Average Price Target
$7.96
▲(137.61% Upside)
Technical Analysis
Ownership Overview
1.47% Insiders
12.30% Mutual Funds
13.63% Other Institutional Investors
60.48% Public Companies and
Individual Investors